Skip to main content
. Author manuscript; available in PMC: 2016 Dec 28.
Published in final edited form as: JAMA. 2016 Jun 28;315(24):2673–2682. doi: 10.1001/jama.2016.7050

Figure 1. Eligibility, Randomization, and Follow-up for Systolic Blood Pressure (SBP) Intervention Trial (SPRINT) Participants Aged 75 Years or Older.

Figure 1

aSystolic blood pressure was required to be between 130 mm Hg and 180 mm Hg for participants taking 0 or 1 medication, 130 mm Hg to 170 mm Hg for participants taking 2 medications or fewer, 130 mm Hg to 160 mm Hg for participants taking 3 medications or fewer, and 130 mm Hg to 150 mm Hg for participants taking 4 medications or fewer.

bIncreased cardiovascular risk was defined as presence of 1 or more of the following: (1) clinical or subclinical cardiovascular disease other than stroke, (2) chronic kidney disease (defined as an estimated glomerular filtration rate of 20 mL/min/1.73m2 to 59 mL/min/1.73m2 based on the 4-variable Modification of Diet in Renal Disease equation and the latest laboratory value within the past 6 months), (3) Framingham risk score for 10-year cardiovascular risk of 15% or greater based on laboratory work done within the past 12 months for lipids, or (4) age of 75 years or older.

HHS Vulnerability Disclosure